Greg Madison of Shield Therapeutics discusses their US expansion, final results & financing agreement

Greg Madison, CEO of Shield Therapeutics #STX discusses their US expansion which has seen a 100% increase in total Accrufer® prescriptions in Q1 '22 as compared to Q4 '21, their final results & financing agreement.

Current Business Updates

· 100% increase in total Accrufer® prescriptions in Q1 '22 as compared to Q4 '21, exceeding 3,900 total prescriptions during the first quarter, with a small 30-person sales team.

o Women's Health practitioners, a rapidly growing segment treating women with underlying diseases leading to iron deficiency, now represents over 50% of Accrufer® prescriptions.

o Continued high Accrufer® demand from the General Practitioners representing the balance of prescriptions.

o Estimated 20 million people in the US with anaemia reflecting a huge medical need.

· 100 million or ~40% of eligible lives now have coverage for Accrufer® by US payers across commercial and Medicaid segments, dramatically expanding access for patients and growing further.

· >1,100 Health Care Providers have been introduced to Accrufer® by participating in Shield sponsored programmes from January to April.

· 700 New First Time Writers of Accrufer® from January to April, indicating growing awareness and interest by healthcare providers.

· FDA approval of Accrufer® product shelf life increased from 24 to 36 months providing additional flexibility in manufacturing and storage timelines.

· Phase 3 paediatric study in the US and UK on track with over 50% of sites active.

· Out-licensing agreement for Accrufer®/Feraccru® with KYE Pharmaceuticals Inc. ("KYE") in Canada in January 2022. In March 2022, KYE submitted their documentation for approval in the Canadian market, expected mid-2023.

To read the full RNS click here